Business Context and Reporting Period
This Form 8-K Current Report, dated June 29, 2023, covers Intensity Therapeutics, Inc., a Delaware corporation and emerging growth company. The filing details the company's Initial Public Offering (IPO) and related corporate governance updates. The offering closed on July 5, 2023.
Key Financial Metrics
- Gross Proceeds: $19,500,000 from the sale of 3,900,000 shares at $5.00 per share.
- Net Proceeds: Approximately $16.2 million after deducting underwriting commissions, discounts, and offering expenses.
- Underwriting Discount: 7.0% ($4.65 purchase price per share).
- Expense Allowances: Accountable expenses up to $175,000 and a non-accountable expense allowance of 1% of gross proceeds.
- Over-Allotment: A 45-day option for up to 585,000 additional shares was granted but not exercised at closing.
Material Changes
The primary material change is the transition from a private to a public company via the IPO. The company sold 3,900,000 shares of Common Stock to The Benchmark Company, LLC, as representative of the underwriters. Additionally, the company issued a warrant to the representative to purchase 273,000 shares (7.0% of the shares sold) at an exercise price of $6.00 per share, exercisable from July 5, 2023, through July 5, 2028.
Guidance, Outlook, and Corporate Actions
Use of Proceeds: The company intends to use net proceeds to initiate and conduct therapeutic studies, fund clinical trials and operations, develop product candidates, and support working capital and general corporate activities.
Corporate Governance: In connection with the offering, the company filed its Sixth Amended and Restated Certificate of Incorporation on June 30, 2023, and adopted Amended and Restated Bylaws effective July 5, 2023.
Risks and Contingencies: The filing notes customary representations, warranties, and indemnification obligations to the underwriters. The summary of the Underwriting Agreement and Warrant is qualified by reference to the full text of the exhibits.
Investor Verification Checklist
- Verify the final number of shares sold if the over-allotment option is exercised within the 45-day window.
- Review the full text of the Underwriting Agreement (Exhibit 10.1) for specific covenants and indemnification liabilities.
- Confirm the terms of the Representative's Warrant (Exhibit 4.1), including the $6.00 exercise price and 5-year expiration.
- Examine the Sixth Amended and Restated Certificate of Incorporation (Exhibit 3.1) for any anti-takeover provisions or director liability limitations.
- Monitor subsequent filings for the actual deployment of the $16.2 million in net proceeds against the stated clinical trial and operational goals.